SUPPORT THE MSK COVID-19 FUND

SUPPORT THE MSK COVID-19 FUND

Give to MSK's greatest needs, research and innovation, or employee relief. Together, we will emerge even stronger

DONATE NOW
AAA DNA

Membership

MSK alumni receive access to a web-based, searchable directory of MSK alumni and admittance to an array of reunions, receptions and networking activities hosted by the Alumni Society.

Learn More
Alumni Banner

Events

Each year, we host several social and educational opportunities designed to reconnect, engage and network with alumni.

Visit our Events page for details of upcoming events and meetings.

Visit the Events Calendar
On Cancer - Surgeons

Get Involved

The Memorial Hospital Alumni Society is a community unlike any other. There are many ways to engage with the Alumni Society. Click below to learn more.

Get Involved
Surgeons

Donations

All alumni are encouraged to make philanthropic gifts to MSK—in lieu of annual dues—to advance alumni community initiatives, foster strong leadership and expertise in every generation of MSK physician-scientists, and accelerate research innovations that optimize patient care.

Donate Now

About Us

MSK Alumni are vital ambassadors and advocates for MSK—and living examples of the far-reaching impact of MSK’s work and dedication to training world-class physicians.

Learn more about the Alumni Society
Dr. Wolchok and Dr. VanDenBrink

Photos From Past Events

To view photos from Memorial Hospital Alumni Society activities, first click on the album then click on any thumbnail photo to view the full-size photo. 

View the photos
View the Photos

Featured Videos

View videos from our latest events, as well as speaking engagements from your fellow alumni. 

See all featured videos
Featured Videos

In the News

msk_oncology

Oncologists Find Controversary With Pembrolizumab Approval in TMB-High Solid Tumors

While pembrolizumab (Keytruda) showed a significant and durable response in patients with treatment-refractory cancers and a tumor mutational burden (TMB) greater than 10 mutations per megabase (mut/Mb), a new analysis suggests that the data used for its approval were too broad and neglect decreased survival data in certain tumor types.1

Read more here

Oncologists Find Controversary With Pembrolizumab Approval in TMB-High Solid Tumors
msk_blood_cancer

Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer

Two patients with advanced Hodgkin lymphoma were told their tumors were so resistant to treatment that hospice was their best option. Then, they were enrolled in a clinical trial of a novel immunotherapy involving so-called natural killer cells. After treatment, they saw complete remission.

Read more here

Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer
msk_aacr

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma

Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab

Read more here

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
More news

Noteworthy News

Dear Alumni,

We invite you to use the form below to add "Noteworthy News" to the alumni news items for all alumni to review. Please note that your news will be reviewed for approval before posting.